News | Coronavirus (COVID-19) | October 17, 2022

Smoking, Diabetes and Obesity - Not Preexisting Heart Disease - Bigger Risk of COVID-19 Death, Study Finds

People with cardiovascular disease still have a high burden of risk factors for severe COVID

People with cardiovascular disease still have a high burden of risk factors for severe COVID

Getty Images


October 17, 2022 —  A national study suggests that risk factors for cardiovascular disease, such as age, smoking and diabetes – not preexisting heart disease – are the main contributors to death and poor outcomes for critically ill COVID-19 patients. 

A team led by Michigan Medicine researchers analyzed outcomes for more than 5,100 patients admitted to intensive care units at 68 centers across the United States with severe COVID between March and June of 2020. Of those patients, 1,174 had either preexisting coronary artery disease, congestive heart failure or atrial fibrillation

Results reveal that patients with cardiovascular disease had close to a 30% higher mortality rate than critically ill COVID patients without the preexisting condition. However, when adjusting for risk factors – including age, sex, race, smoking and others – that relationship was no longer statistically significant. The findings are published in Circulation: Cardiovascular Quality and Outcomes. 

“The fact that the association between cardiovascular disease and death was so heavily diminished when accounting for comorbidities suggests that cardiovascular risk factors rather than preexisting heart disease are the main contributors to in-hospital death in patients with severe COVID-19,” said senior author Salim Hayek, M.D., an assistant professor of internal medicine and medical director at the University of Michigan Health Frankel Cardiovascular Center Clinics. 

A total of 34.6% of patients died within 28 days and nearly 18% suffered a cardiovascular event, such as cardiac arrest or myocarditis. Researchers say the association between such events and death did not differ between patients with and without preexisting heart disease. 

Cardiovascular disease is a common condition among patients who suffer severe COVID illness, given its prevalence among older adults and associated chronic inflammation. In the study, age, obesity and diabetes were much stronger predictors of death due to COVID. 

Regardless of whether a patient had preexisting heart disease, researchers found the presence of myocardial injury was associated with cardiovascular events and death. Myocardial injury was common among patients in the ICU, occurring in nearly half of patients who had heightened levels of troponin, a protein released when the heart muscle is damaged. Patients with the highest troponin measurements were nearly three times more likely to die than those without myocardial injury. 

“While patients with severe COVID commonly had signs of cardiac injury, our findings reinforce COVID-19 as a pulmonary disease with multi-organ injury related to systemic inflammation,” Hayek said. “The evidence of heart damage that we frequently see in patients with severe COVID-19 is more likely a reflection of the severity of the illness and the stress it imparts on all organs rather than the development of new complications or the exacerbation of preexisting heart disease.” 

The findings should not minimize the fact that patients with cardiovascular disease are still at risk for death due to COVID-19, as they have a high burden of risk factors for the disease, such as diabetes, hypertension and smoking, says co-first author Alexi Vasbinder, Ph.D., R.N., a postdoctoral fellow in internal medicine. 

“We are currently working on studies to further define groups of patients with COVID-19 at highest risk for severe outcomes, such as those with advanced heart failure or coronary artery disease,” Vasbinder said. 

For more information: https://med.umich.edu/ 


Related Content

News | Heart Failure

February 15, 2024 — Canary Medical, a medical data company focused on the development and commercialization of its ...

Home February 15, 2024
Home
News | Heart Failure

February 12, 2023 — A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully ...

Home February 12, 2024
Home
News | Heart Failure

January 30, 2024 — Researchers from the Johns Hopkins Bloomberg School of Public Health have developed a single ...

Home January 30, 2024
Home
News | Heart Failure

January 23, 2024 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

Home January 23, 2024
Home
News | Heart Failure

January 16, 2024 — Cardiac Dimensions, a leader in the development of innovative and minimally invasive treatment ...

Home January 16, 2024
Home
News | Heart Failure

November 30, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home November 30, 2023
Home
News | Heart Failure

November 30, 2023 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

Home November 30, 2023
Home
News | Heart Failure

November 16, 2023 — Mount Sinai’s Cardiovascular Research Institute is sending bioengineered human heart muscle cells ...

Home November 16, 2023
Home
News | Heart Failure

November 16, 2023 — A smartphone app using artificial intelligence technology to detect changes in the voice of a person ...

Home November 16, 2023
Home
News | Heart Failure

November 14, 2023 — Deepak Srivastava, MD, president of Gladstone Institutes and a renowned cardiovascular researcher ...

Home November 14, 2023
Home
Subscribe Now